Received Apr 6, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (PRIORIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | IM |
Intramuscular Administration of Priorix; This non-serious case was reported by a other health professional via call center representative and described the occurrence of subcutaneous injection formulation administered by other route in a 28-year-old female patient who received MMR (Priorix) for prophylaxis. On 28-MAR-2026, the patient received Priorix (intramuscular). On 28-MAR-2026, an unknown time after receiving Priorix, the patient experienced subcutaneous injection formulation administered by other route (Verbatim: Intramuscular Administration of Priorix). The outcome of the subcutaneous injection formulation administered by other route was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 31-MAR-2026 The pharmacy intern reported a nurse administered the Priorix vaccine intramuscularly to a patient on 28-Mar-2026. The batch number was not provided upon follow up with the reporter.